Natera, a global leader in cell-free DNA (cfDNA) testing and molecular diagnostics, has announced the appointment of Solomon Moshkevich as its new Chief Executive Officer, effective immediately. Moshkevich, a 15-year veteran of the Austin, Texas-based company, succeeds Steve Chapman, who served as CEO for more than seven years. The leadership transition, announced alongside the company’s third-quarter financial results, marks a pivotal moment for the diagnostics firm as it seeks to solidify its dominance in the oncology, women’s health, and organ health markets. While the company reported a robust 34.1% year-over-year revenue increase to $794 million for the quarter, the sudden nature of the executive handover triggered a sharp 14% decline in Natera’s stock price, which settled at $312.98 by midday Friday.
A Legacy of Clinical Innovation and Commercial Expansion
Solomon Moshkevich’s ascent to the CEO role is the culmination of a decade and a half of leadership within Natera. Having most recently served as the President of Clinical Diagnostics, Moshkevich is widely credited as a primary architect of the company’s most successful clinical programs. During his tenure, he played a central role in the development, clinical validation, and commercial rollout of Natera’s core technology suite.
Moshkevich’s influence spans the company’s three primary verticals. In women’s health, he oversaw the scaling of Panorama, a non-invasive prenatal test (NIPT) that has become a standard of care for screening chromosomal abnormalities. In the organ health sector, he championed Prospera, a donor-derived cell-free DNA test designed to assess the risk of organ rejection in transplant recipients. However, his most significant contribution is perhaps the development of Signatera, Natera’s personalized molecular residual disease (MRD) test.
As the company’s first general manager of oncology, Moshkevich led the strategic pivot that transformed Natera from a prenatal-focused laboratory into a powerhouse of precision oncology. Signatera has redefined how clinicians monitor cancer recurrence, utilizing a patient’s own tumor profile to detect trace amounts of circulating tumor DNA (ctDNA) months before traditional imaging can identify a relapse. Under Moshkevich’s guidance, Signatera has secured extensive Medicare coverage and been integrated into numerous clinical trials, establishing a high barrier to entry for competitors.
The Departure of Steve Chapman and Investor Sentiment
The transition comes as Steve Chapman steps down from the chief executive role, a position he held since 2017. During Chapman’s tenure, Natera transitioned from a small-cap diagnostics firm into a multi-billion-dollar enterprise, consistently outperforming market expectations. In an official statement, Chapman expressed confidence in the timing of the move, noting that Moshkevich has been "deeply involved with every major decision the company has made."
Chapman will not be leaving the company entirely; he is slated to serve as a consultant for an "extended period" and will remain an advisor to the Board of Directors. Despite these assurances of a smooth handover, the market reacted with volatility. Analysts from TD Cowen and BNP Paribas noted that while Moshkevich is a highly qualified internal successor, the "immediacy" and "unexpected" nature of the announcement caught investors off guard.
TD Cowen analyst Dan Brennan highlighted that Chapman was synonymous with Natera’s consistent execution and operational stability. The nearly 14% drop in share price reflects a "digestion period" for the market, as investors recalibrate their expectations under new leadership. However, financial experts largely agree that the underlying fundamentals of the company remain strong, with Moshkevich’s long-standing history providing the necessary continuity to maintain Natera’s current trajectory.
Record-Breaking Financial Performance in Q3 2024
Lost somewhat in the noise of the leadership change was Natera’s exceptional financial performance for the third quarter. The company reported total revenue of $794 million, representing a 34.1% increase compared to the $592 million reported in the same period last year. This growth was driven primarily by a surge in testing volume, particularly in the oncology segment.
Key financial highlights from the third quarter include:
- Revenue Growth: The $794 million figure exceeded analyst consensus estimates, fueled by the continued adoption of Signatera in the community oncology setting.
- Volume Increase: Natera processed approximately 725,000 tests in Q3, a significant jump from previous quarters, indicating a deepening market penetration.
- Margin Improvement: The company continues to move toward sustained profitability, narrowing its net losses as it scales its laboratory operations and optimizes its reimbursement processes.
The financial results underscore the "beat and raise" pattern that Natera has established over the past several years. Despite the stock’s temporary tumble, the company’s ability to generate nearly $800 million in quarterly revenue places it at the top of the molecular diagnostics industry, ahead of many peers who have struggled with slowing growth and regulatory headwinds.
Strategic Vision: The Next Frontier of Precision Medicine
Upon taking the helm, Moshkevich outlined a forward-looking vision centered on deeper diagnostic insights and expanded patient access. His strategy focuses on moving beyond simple detection to providing comprehensive management tools at the point of care.
"In the years ahead, we intend to generate more diagnostic insights from every clinical sample, bring novel technologies to new patient populations, integrate more seamlessly at the point of care, and help shape the next frontier of precision medicine," Moshkevich stated.
This vision includes the integration of artificial intelligence and machine learning to refine the predictive capabilities of Natera’s assays. By leveraging the massive datasets generated by millions of tests, Natera aims to provide clinicians with highly personalized "treatment response" metrics, helping to determine not just if a cancer has returned, but how a specific patient is responding to immunotherapy or chemotherapy in real-time.
Furthermore, Moshkevich is expected to prioritize international expansion. While Natera has a dominant footprint in the United States, the global market for MRD testing and prenatal screening remains largely untapped. The company’s ability to navigate diverse regulatory environments in Europe and Asia will be a key metric of Moshkevich’s success in his first few years as CEO.
Analyzing the Industry Context and Competitive Landscape
Natera’s leadership change occurs during a period of significant upheaval in the diagnostics industry. Regulatory bodies, including the U.S. Food and Drug Administration (FDA), have increased scrutiny on Laboratory Developed Tests (LDTs), proposing new frameworks that could require more rigorous clinical data for diagnostic assays.
Natera is well-positioned to navigate these changes due to the extensive peer-reviewed data supporting Signatera and Panorama. Moshkevich’s background in regulatory and quality affairs—one of the many teams he led during his 15-year tenure—will be an asset as the company adapts to evolving federal guidelines.
In the competitive landscape, Natera continues to vie for market share against companies like Guardant Health and Exact Sciences. While Guardant has focused heavily on liquid biopsy for early cancer screening, Natera’s Signatera has maintained a "first-mover" advantage in the MRD space. The challenge for Moshkevich will be to defend this territory while simultaneously innovating in new areas, such as the use of cfDNA to monitor chronic conditions beyond oncology and transplantation.
Timeline of Key Milestones Under Moshkevich’s Leadership
To understand the confidence the Board has in Moshkevich, one must look at the chronological growth of Natera’s clinical portfolio over the last decade:
- 2013-2015: Moshkevich helps lead the commercialization of Panorama NIPT, establishing Natera as a leader in reproductive health.
- 2017: Under the Chapman-Moshkevich partnership, Natera launches Signatera, the first personalized ctDNA test for MRD.
- 2019: The company expands into organ health with the launch of Prospera, targeting the high-need kidney transplant market.
- 2021-2023: Moshkevich leads the effort to secure expanded Medicare coverage for Signatera in colorectal cancer, breast cancer, and muscle-invasive bladder cancer.
- 2024: Natera achieves record-breaking revenue of $794 million in Q3, leading to Moshkevich’s appointment as CEO.
Conclusion and Market Outlook
The appointment of Solomon Moshkevich as CEO of Natera signals a transition from a phase of rapid, broad-based growth to one of specialized, data-driven dominance. While the sudden departure of Steve Chapman caused a momentary shock to the company’s valuation, the choice of a 15-year veteran with deep technical and commercial expertise suggests that Natera’s core strategy will remain intact.
As Moshkevich takes charge, the industry will be watching closely to see how he handles the dual pressures of maintaining high revenue growth while steering the company toward consistent GAAP profitability. With a robust pipeline of new technologies and a massive clinical database, Natera remains at the forefront of the diagnostic revolution. The leadership transition, though abrupt, places a seasoned clinical expert at the helm during a time when the "science" of diagnostics is becoming more complex and more vital than ever before. For Natera, the goal remains clear: to provide the insights that allow for earlier interventions, ultimately saving lives through the power of molecular technology.
